Please ensure Javascript is enabled for purposes of website accessibility

Nano-X Imaging: Buy the Dip?

By Taylor Carmichael - Mar 3, 2021 at 6:25AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The X-ray disrupter is almost 50% off its highs.

Just a couple of weeks ago, shares of Nano-X Imaging (NNOX -5.50%) traded hands for $87 per share. Now you can buy that same stock for $46 a share. That's a lot cheaper. Does that make it a buy?

That question is actually a little tricky. A cheap stock price can mislead people into buying shares of a mediocre company, or even a bad company. Amazing companies have stock prices that go up over the long term. If you own shares of a less-than-amazing company, and it's clobbered by its rivals, the stock will get cheaper. So is Nano-X's cheaper price an opportunity or a warning sign?

Two female doctors in blue scrubs stand in front of x-ray images, pointing out various elements.

Image source: Getty Images

Beware the value trap

One of my early lessons in the stock market involved Cisco. Twenty years ago, Cisco was the No. 1 networking company in the world. And I was trying to decide whether I should buy shares of Cisco, or the No. 2 networking company, 3Com. I bought shares of 3Com, and my reasoning was that it was a better deal, because the stock was a lot cheaper. You probably haven't heard of 3Com. That's because it dissipated into nothingness. Meanwhile, Cisco investors got rich.

The lesson I learned is that you always want to buy shares of the strongest companies in the stock market -- even if the stock is expensive. Winning companies usually continue to win and dominate rivals. And of course, the price of excellence is high. So most of the stocks I buy now are actually pretty expensive, trading at big multiples of estimated future earnings.

While Nano-X stock is a lot cheaper than it was, the stock is actually very expensive, vis-a-vis the whole market. If Nano-X had earnings, its price-to-earnings (P/E) ratio would be off the charts. The value trap you want to avoid is buying shares of an inferior company because the stock is cheap. Nano-X is not only the best at what it does, it's one-of-a-kind. So I don't think this is a value trap; you can simply pay a cheaper price for an excellent company today than you could have a few weeks ago.   

Technology starts off rare (and expensive), and becomes ubiquitous (and cheap)

Nano-X is introducing a new kind of X-ray. X-ray technology has been in medical use for over 120 years. Computer-assisted tomography (CAT) scanners and medical resonance imaging (MRI), which are commonplace in hospitals, cost over $1 million and up to $3 million.

Now, Nano-X is threatening to disrupt the entire X-ray industry. The typical X-ray machine is expensive because it requires a massive amount of heat to work -- up to 3,600 degrees Fahrenheit. Nano-X's machine works at room temperature. Using nanoparticles, Nano-X has discovered a way to digitize the power source for an X-ray device. This advancement makes it a far cheaper device to manufacture. If and when Nano-X earns regulatory approval, the company will offer its X-ray device to hospitals for $10,000, or even cheaper than that. It's this cheap price that is causing so much early consternation.

Improved technology often makes things cheaper. The U.S. spent $28 billion to put a man on the moon. Adjusted for inflation, we actually spent $283 billion in today's dollars. And it's been estimated that the iPhone in your pocket has 100,000 times more computational power than the computers that put a man on the moon.

That sort of dramatic price reduction hasn't happened with X-rays -- yet. The X-ray market is dominated by huge conglomerates like Fujifilm (FUJIY -0.22%), General Electric (GE -1.57%), and Siemens AG (SIEGY -4.39%). Nano-X's breakthrough might radically change this industry. And it speaks volumes that the early venture capital given to Nano-X came from industry veterans like Fujifilm, as well as manufacturers like SK Telecom (SKM -4.21%) and Foxconn, the makers of the iPhone. Last year, when Nano-X was still private, it received $26 million in funding from this group.

Expensive in the short term, cheap in the long term

Make no mistake, Nano-X is still an expensive stock, even though it's price has dropped in recent months. Right now, the company is like a biotech stock without any drugs on the market. Later this year, Nano-X expects to receive FDA clearance and to start marketing its device in the U.S. starting in its Q4. I expect shares to dramatically spike when this happens, and to continue shooting higher over the next decade.

For long-term investors, it actually doesn't matter if you buy your shares at $87 or $46. While that price differential seems large now, as Nano-X scales and becomes much larger over the next decade, these 2021 share price differences will recede in importance. Does it matter if you bought Apple at $1 or $2? Not really. When you're early to the game, small investments can create massive returns over time.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Nano-X Imaging Ltd. Stock Quote
Nano-X Imaging Ltd.
$9.45 (-5.50%) $0.55
Apple Inc. Stock Quote
Apple Inc.
$140.82 (-5.64%) $-8.42
General Electric Company Stock Quote
General Electric Company
$75.20 (-1.57%) $-1.20
Cisco Systems, Inc. Stock Quote
Cisco Systems, Inc.
$48.36 (-4.43%) $-2.24
Siemens Aktiengesellschaft Stock Quote
Siemens Aktiengesellschaft
$58.80 (-4.39%) $-2.70
SK Telecom Co.,Ltd Stock Quote
SK Telecom Co.,Ltd
$25.47 (-4.21%) $-1.12
FUJIFILM Holdings Corporation Stock Quote
FUJIFILM Holdings Corporation
$54.05 (-0.22%) $0.12

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.